Therapeutic effects of exogenous surfactant enriched with dextran in newborn rabbits with respiratory failure induced by airway instillation of albumin
- PMID: 18032077
- DOI: 10.1016/j.pupt.2007.10.003
Therapeutic effects of exogenous surfactant enriched with dextran in newborn rabbits with respiratory failure induced by airway instillation of albumin
Abstract
The aim of the study was to investigate lung function and morphology in newborn rabbits with acute respiratory failure induced by airway instillation of albumin and to test whether the therapeutic effect of exogenous modified natural surfactant could be enhanced by addition of dextran. Rabbits (gestational age 29 days) were ventilated with 100% O2 and tidal volume 8-10 ml/kg. Respiratory failure was induced by tracheal instillation of albumin (50 or 100mg/ml; 2 ml/kg) and the instillation was repeated 15 min later. Surfactant (Curosurf, 200mg/kg) with or without addition of dextran (30 mg/ml) was administered 15 min after the second dose of albumin and animals were then ventilated for another 60 min. In one series of experiments, instillation of albumin was followed by administration of diluted Curosurf (40 mg/kg) with or without dextran (30 mg/ml). Animals with initial lung-thorax compliance (CLT)<0.6 ml/kg cm H2O were directly treated with surfactant without previous instillation of albumin. Animals treated with a larger dose of Curosurf (200mg/kg) showed a significant increase in CLT at 60 min with no difference between groups receiving high or low dose of albumin. Addition of dextran to Curosurf at high dose (200mg/kg) reduced the therapeutic response (P<0.05 vs. Curosurf without dextran). After treatment with low-dose Curosurf (40 mg/kg) CLT increased more prominently after Curosurf+dextran than after non-enriched surfactant (P<0.05). Dextran potentiated the treatment effect of Curosurf at suboptimal dose (40 mg/kg) but not at high dose (200mg/kg) in animals with low-grade surfactant deficiency or respiratory failure induced by airway instillation of albumin.
Similar articles
-
Biophysical and physiological properties of a modified porcine surfactant enriched with surfactant protein A.Eur Respir J. 1997 Sep;10(9):1967-74. doi: 10.1183/09031936.97.10091967. Eur Respir J. 1997. PMID: 9311487
-
Bronchoalveolar lavage with pulmonary surfactant/dextran mixture improves meconium clearance and lung functions in experimental meconium aspiration syndrome.Eur J Pediatr. 2008 Aug;167(8):851-7. doi: 10.1007/s00431-007-0596-7. Epub 2007 Oct 19. Eur J Pediatr. 2008. PMID: 17952467
-
Experimental neonatal respiratory failure induced by lysophosphatidylcholine: effect of surfactant treatment.J Appl Physiol (1985). 1999 Feb;86(2):633-40. doi: 10.1152/jappl.1999.86.2.633. J Appl Physiol (1985). 1999. PMID: 9931201
-
Probable adverse reaction to a pharmaceutical excipient.Arch Dis Child Fetal Neonatal Ed. 2004 Mar;89(2):F184. doi: 10.1136/adc.2002.024927. Arch Dis Child Fetal Neonatal Ed. 2004. PMID: 14977910 Free PMC article. Review.
-
Dextran-based Drug Delivery Approaches for Lung Diseases: A Review.Curr Drug Deliv. 2024;21(11):1474-1496. doi: 10.2174/0115672018267737231116100812. Curr Drug Deliv. 2024. PMID: 38243938 Review.
Cited by
-
Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin.PLoS One. 2018 Sep 20;13(9):e0204050. doi: 10.1371/journal.pone.0204050. eCollection 2018. PLoS One. 2018. PMID: 30235278 Free PMC article.
-
New surfactant with SP-B and C analogs gives survival benefit after inactivation in preterm lambs.PLoS One. 2012;7(10):e47631. doi: 10.1371/journal.pone.0047631. Epub 2012 Oct 16. PLoS One. 2012. PMID: 23091635 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical